AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO

AcelRx Pharmaceuticals ACRX and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO™ (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital, hospice, nursing home or other medically supervised setting.  ZALVISO, a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device is AcelRx's lead program.  AcelRx retains all rights in remaining countries, including the U.S. and Asia. Under the terms of the agreement, AcelRx will receive an upfront cash payment of $30 million.  AcelRx is eligible to receive approximately $220 million in additional milestone payments, based upon successful regulatory and product development efforts and net sales target achievements.  Grunenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, See full press release